Impact of Type II LRRK2 inhibitors on signaling and mitophagy

Much effort has been devoted to the development of selective inhibitors of the LRRK2 as a potential treatment for LRRK2 driven Parkinson's disease. In this study, we first compare the properties of Type I (GSK3357679A and MLi-2) and Type II (GZD-824, Rebastinib and Ponatinib) kinase inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasegian, Anna, Singh, Francois, Ganley, Ian G., Reith, Alastair D., Alessi, Dario R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Signaling
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589421/
https://www.ncbi.nlm.nih.gov/pubmed/34515301
http://dx.doi.org/10.1042/BCJ20210375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589421/
https://www.ncbi.nlm.nih.gov/pubmed/34515301
http://dx.doi.org/10.1042/BCJ20210375

Ejemplares similares